Cocrystals of a Coumarin Derivative: an Efficient Approach Towards Anti-leishmanial Cocrystals Against MIL-resistant Leishmania Tropica

Overview

Journal IUCrJ

Date 2024 Mar 1

PMID 38427455

Authors

Muhammad Shahbaz

Saba Farooq

M Iqbal Choudhary

Sammer Yousuf

Affiliations

Soon will be listed here.

Abstract

Leishmaniasis is a neglected parasitic tropical disease with numerous clinical manifestations. One of the causative agents of cutaneous leishmaniasis (CL) is Leishmania tropica (L. tropica) known for causing ulcerative lesions on the skin. The adverse effects of the recommended available drugs, such as amphotericin B and pentavalent antimonial, and the emergence of drug resistance in parasites, mean the search for new safe and effective anti-leishmanial agents is crucial. Miltefosine (MIL) was the first recommended oral medication, but its use is now limited because of the rapid emergence of resistance. Pharmaceutical cocrystallization is an effective method to improve the physicochemical and biological properties of active pharmaceutical ingredients (APIs). Herein, we describe the cocrystallization of coumarin-3-carboxylic acid (CU, 1a; 2-oxobenzopyrane-3-carboxylic acid, CHO) with five coformers [2-amino-3-bromopyridine (1b), 2-amino-5-(trifluoromethyl)-pyridine (1c), 2-amino-6-methylpyridine (1d), p-aminobenzoic acid (1e) and amitrole (1f)] in a 1:1 stoichiometric ratio via the neat grinding method. The cocrystals 2-6 obtained were characterized via single-crystal X-ray diffraction, powder X-ray diffraction, differential scanning calorimetry and thermogravimetric analysis, as well as Fourier transform infrared spectroscopy. Non-covalent interactions, such as van der Waals, hydrogen bonding, C-H...π and π...π interactions contribute significantly towards the packing of a crystal structure and alter the physicochemical and biological activity of CU. In this research, newly synthesized cocrystals were evaluated for their anti-leishmanial activity against the MIL-resistant L. tropica and cytotoxicity against the 3T3 (normal fibroblast) cell line. Among the non-cytotoxic cocrystals synthesized (2-6), CU:1b (2, IC = 61.83 ± 0.59 µM), CU:1c (3, 125.7 ± 1.15 µM) and CU:1d (4, 48.71 ± 0.75 µM) appeared to be potent anti-leishmanial agents and showed several-fold more anti-leishmanial potential than the tested standard drug (MIL, IC = 169.55 ± 0.078 µM). The results indicate that cocrystals 2-4 are promising anti-leishmanial agents which require further exploration.

References

Beillerot A, Dominguez J, Kirsch G, Bagrel D . Synthesis and protective effects of coumarin derivatives against oxidative stress induced by doxorubicin. Bioorg Med Chem Lett. 2008; 18(3):1102-5. DOI: 10.1016/j.bmcl.2007.12.004. View

Mackenzie C, Spackman P, Jayatilaka D, Spackman M . model energies and energy frameworks: extension to metal coordination compounds, organic salts, solvates and open-shell systems. IUCrJ. 2017; 4(Pt 5):575-587. PMC: 5600021. DOI: 10.1107/S205225251700848X. View

Aakeroy C, Grommet A, Desper J . Co-crystal screening of diclofenac. Pharmaceutics. 2013; 3(3):601-14. PMC: 3857085. DOI: 10.3390/pharmaceutics3030601. View

Malamatari M, Ross S, Douroumis D, Velaga S . Experimental cocrystal screening and solution based scale-up cocrystallization methods. Adv Drug Deliv Rev. 2017; 117:162-177. DOI: 10.1016/j.addr.2017.08.006. View

Perez-Victoria F, Sanchez-Canete M, Seifert K, Croft S, Sundar S, Castanys S . Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat. 2006; 9(1-2):26-39. DOI: 10.1016/j.drup.2006.04.001. View

Hussain H, Al-Harrasi A, Al-Rawahi A, Green I, Gibbons S . Fruitful decade for antileishmanial compounds from 2002 to late 2011. Chem Rev. 2014; 114(20):10369-428. DOI: 10.1021/cr400552x. View

Nugrahani I, Jessica M . Amino Acids as the Potential Co-Former for Co-Crystal Development: A Review. Molecules. 2021; 26(11). PMC: 8198002. DOI: 10.3390/molecules26113279. View

Venkatesan P, Thamotharan S, Ilangovan A, Liang H, Sundius T . Crystal structure, Hirshfeld surfaces and DFT computation of NLO active (2E)-2-(ethoxycarbonyl)-3-[(1-methoxy-1-oxo-3-phenylpropan-2-yl)amino] prop-2-enoic acid. Spectrochim Acta A Mol Biomol Spectrosc. 2015; 153:625-36. DOI: 10.1016/j.saa.2015.09.002. View

Murray H, Berman J, Davies C, Saravia N . Advances in leishmaniasis. Lancet. 2005; 366(9496):1561-77. DOI: 10.1016/S0140-6736(05)67629-5. View

10.

Lacy A, OKennedy R . Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des. 2004; 10(30):3797-811. DOI: 10.2174/1381612043382693. View

11.

Borges F, Roleira F, Milhazes N, Santana L, Uriarte E . Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr Med Chem. 2005; 12(8):887-916. DOI: 10.2174/0929867053507315. View

12.

Castro-Gomes T, Almeida-Campos F, Calzavara-Silva C, da Silva R, Frezard F, Horta M . Membrane binding requirements for the cytolytic activity of Leishmania amazonensis leishporin. FEBS Lett. 2009; 583(19):3209-14. DOI: 10.1016/j.febslet.2009.09.005. View

13.

. Control of the leishmaniases. World Health Organ Tech Rep Ser. 2011; (949):xii-xiii, 1-186, back cover. View

14.

Desjeux P . Human leishmaniases: epidemiology and public health aspects. World Health Stat Q. 1992; 45(2-3):267-75. View

15.

Seifert K, Matu S, Perez-Victoria F, Castanys S, Gamarro F, Croft S . Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents. 2003; 22(4):380-7. DOI: 10.1016/s0924-8579(03)00125-0. View

16.

Shahbaz M, Khan U, Chaudhary M, Yousuf S . A new bioactive cocrystal of coumarin-3-carboxylic acid and thiourea: detailed structural features and biological activity studies. Acta Crystallogr C Struct Chem. 2022; 78(Pt 3):192-200. DOI: 10.1107/S205322962200081X. View

17.

Matos M, Teran C, Perez-Castillo Y, Uriarte E, Santana L, Vina D . Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors. J Med Chem. 2011; 54(20):7127-37. DOI: 10.1021/jm200716y. View

18.

Mondelaers A, Sanchez-Canete M, Hendrickx S, Eberhardt E, Garcia-Hernandez R, Lachaud L . Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes. PLoS One. 2016; 11(4):e0154101. PMC: 4849676. DOI: 10.1371/journal.pone.0154101. View

19.

Sanchez-Canete M, Carvalho L, Perez-Victoria F, Gamarro F, Castanys S . Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob Agents Chemother. 2009; 53(4):1305-13. PMC: 2663093. DOI: 10.1128/AAC.01694-08. View

20.

Hendrickx S, Inocencio da Luz R, Bhandari V, Kuypers K, Shaw C, Lonchamp J . Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol. PLoS Negl Trop Dis. 2012; 6(5):e1664. PMC: 3362622. DOI: 10.1371/journal.pntd.0001664. View